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Background: Effective and tolerable therapeutic strategies for patients with refractory
persistent epithelial defects (PEDs) are limited and generally provide poor outcomes. This
retrospective case review describes four refractory cases of PEDs associated with recurrent
corneal erosions (RCEs) and dry eye disease (DED), which were successfully treated with
cyclosporine eye drops.
Methods: Patients were treated with cyclosporine A 0.05% eye drops twice a day for at least
12 months. At enrolling time, each patient was asked to suspend topical steroids or other eye
drops used for ocular surface abnormalities with the exception of lubricants and eye washing.
A complete evaluation of ocular surface symptoms was performed including the McMonnies
Dry Eye Questionnaire, Ocular Surface Disease Index, slit-lamp biomicroscopy, ﬂuorescein
break-up time, the ﬂuorescein staining of the cornea and conjunctiva (according to the
Oxford grading system), the Schirmer I test, and the meibomian secretion after digital
pressure application on the lids. This set of exams was carried out at baseline and repeated
at all follow-up assessments.
Results: All participants that did not beneﬁt from previous therapies, including corticosteroids
tapering schedule, showed an important improvement in the clinical picture after two months
with topical cyclosporine medication. Moreover, after 12 months of continuous therapy, all
patients showed a clinical improvement in DED signs and symptoms, related to the absence of
new RCE episodes. The treatment was well tolerated, and no adverse effects were reported.
Conclusion: Although a small number of cases were available of our analysis, the treatment
with cyclosporine eye drops represents a promising approach in the management of refrac-
tory PEDs with associated ocular comorbidities, since it may reduce the RCE episodes and
improve the tear ﬁlm stability, in absence of systemic or local side effects.
Keywords: dry eye disease, persistent epithelial defects, cyclosporine eye drops,
recurrentcorneal erosion, corneal adhesion
Introduction
A healthy corneal epithelium is fundamental to prevent damages or infections of the
deeper ocular structures, in order to permit, in conjunction with the tear ﬁlm, a normal
vision.1,2 Accordingly, several corneal epithelial diseases may lead to devastating
consequences to the overall ocular health.3,4 In this sense, corneal epithelial defects
are focal areas of epithelial loss, and therefore local regions of minor defenses of the
ocular surface.5
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Clinically, epithelial defects may be long lasting when
the alterations remain at least two weeks. In these cases,
they are named “Persistent Epithelial Defects” (PEDs).6
Areas of epithelial loss can be easily revealed by ﬂuores-
cein dye during biomicroscopic evaluation.5
A variable number of PEDs may lead to recurrent, pain-
ful episodes of breakdown of corneal epithelium that are
deﬁned as recurrent corneal erosions (RCEs). Each episode
of RCE is characterized by the sudden onset of eye pain,
redness, and photophobia, usually at night or upon awaken-
ing. RCE episodes could last from hours to days.7 There are
different causes of PEDs, such as epithelial/limbal stem cell
deﬁciency, inﬂammatory diseases, neurotrophic diseases
(common causes include diabetes, herpetic infection, and
nerve damage from ocular surgery), and mechanical factors,
especially abnormal lid pathologies.1
On the other hand, dry eye disease (DED) is a set of
disorders of the ocular surface, which can lead to ocular dis-
comfort, pain, blurred vision, and other symptoms and signs.
DED represents a potential, mechanical, and inﬂammatory
cause of PEDs. In 2017, the International Dry Eye WorkShop
(DEWS) deﬁnedDEDas a “multifactorial disease of the ocular
surface” deﬁned by a loss of homeostasis of the tear ﬁlm with
ocular surface inﬂammation and damage, as well as neurosen-
sory abnormalities.8 DED may be episodic or chronic. In
particular, when the disease becomes chronic and severe, if
untreated, patients may even develop ocular surface damage.9
Although there are several treatment strategies for
PEDs, no topical treatment demonstrated to be overall
effective for ocular surface damage, ocular dryness, and
the recurrent breakdown of the epithelium.
Topical cyclosporine A 0.05% is an immunomodulatory
agent that has been shown to reduce chronic ocular surface
inﬂammation by decreasing the cell-mediated inﬂammatory
responses. For these reasons, it has been approved for the
treatment of DED by the US Food and Drug Administration
(FDA) since April 2003, but its potential in other ocular
surface diseases is still poorly understood.
In this case series, we topically administered cyclosporine
A 0.05% in patients with PEDs associated with DED and
RCEs to assess its potential role on the ocular surface healing
and in reducing the recurrence rate of corneal erosions.
Materials and methods
Subjects and study procedure
This descriptive, retrospective study was conducted at the
Eye Clinic of the Department of Surgical Sciences,
University of Cagliari, Italy. The study adhered to the
tenets of the Declaration of Helsinki and was approved
by the Ofﬁce of Research Ethics, University of Cagliari.
All subjects signed informed consents prior to their parti-
cipation in the study.
Four consecutive patients (one male and three females)
suffering from ocular discomfort symptoms attributable to
PEDs associated with DED and RCEs were referred to our
Eye Clinic from January 2015 to December 2017.
Patients were examined at baseline and on the
15th day, and on the 2nd, 6th, and 12th month after the
onset of the therapy.
Inclusion criteria were as follows: recalcitrant PEDs,
DED with ocular discomfort symptoms (ie, dryness, sore-
ness, scratchiness, burning, and grittiness), and history of
RCEs (presenting by pain, redness, and photophobia).
Exclusion criteria included conjunctivitis or different
active ocular inﬂammation or infection.
At enrolling time, each patient was asked to suspend
topical steroids or other eye drops used for ocular surface
abnormalities with the exception of lubricants and eye
washing. Thus, patients were treated with cyclosporine
A 0.05% eye drops twice a day for at least 12 months.
Patients’ medical history and clinical
picture
Patient 1 and 2
Two of the study patients were women, aged 56 and 64
years, who complained about DED symptoms for ﬁve and
two years, respectively. They also referred monocular
recurrent episodes of pain, redness, and photophobia (at
least one episode per month) usually starting on the ﬁrst
awakening. In the months before the ﬁrst visit, patients
consulted other ophthalmologists, thus receiving topical
eye drops such lubricants and steroids, with temporary
and partial improvement of ocular symptoms. At the slit-
lamp evaluation, they showed multiple PEDs in one eye.
General anamnesis was unremarkable in both cases.
Patient 3
The third patient was a 25-year-old woman, with a long
history of DED (for at least 6 years) unsuccessfully treated
with ocular lubricants and topical steroids. Clinically, she
showed a PED in the lower quadrant of the right eye. She
also referred recurrent episodes of acute pain (more than
three times per month) in the left eye due to RCEs epi-
sodes despite the use of bandage contact lens. During
anamnesis, patient reported suffering type 1 diabetes
Napoli et al Dovepress
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mellitus (T1DM), anemia, numerous food allergies, and
autoantibody positivity (ANA and ANCA).
Patient 4
The fourth patient was a 41-year-old man, who developed
a PED in the left eye after herpes simplex keratitis. For
about two years, he has been complaining of monthly
episodes of pain, photophobia, and redness in the right
eye. He was treated with inhibitors of matrix metalloprotei-
nase-9 (oral doxycycline 50 mg two times daily) associated
with lubricant eye drops, topical steroids, and eye washing
without substantial beneﬁts. Clinically, he presented a single
PED in the left eye associated with a mild form of DED.
General anamnesis was unremarkable.
Clinical assessment
At the ﬁrst evaluation, the data collected included the best
corrected visual acuity (BCVA) expressed in logMAR score,
the intraocular pressure (IOP) determined using Goldmann
tonometer, and general/ocular anamnesis. (Table 1). Medical
records of patients were reviewed retrospectively.
On clinical assessment, a complete evaluation of ocular
surface signs and symptoms was performed as reported in
previous studies under controlled environmental
conditions.10–12 In particular, a complete evaluation of
ocular surface symptoms was performed using
McMonnies Dry Eye Questionnaire and Ocular Surface
Disease Index (OSDI). These questionnaires provide
a score that represents the degree of severity of the DED
condition or symptoms. With regard to the McMonnies
score, the classiﬁcation of relative DED grade is as fol-
lows: if score is less than 10, it means no DED; between
10 and 20, DED is mild; more than 20, DED is considered
severe. With respect to the OSDI score, relative DED
grade classiﬁcation is as follows: if score is less than 12,
it means no DED; between 13 and 22, DED is mild;
between 23 and 32, DED is moderate; more than 33,
DED is considered severe.
In addition, the ocular surface was analyzed using by
slit-lamp biomicroscopy (Figures 1 and 2). After the instilla-
tion of ﬂuorescein dye in the tear ﬁlm (blue cobalt light with
yellow ﬁlter Wratten n.12), we evaluated the ﬂuorescein
break-up time (FBUT), the ﬂuorescein staining of the cornea
and conjunctiva (according to the Oxford grading system),
the Schirmer I test, and the meibomian secretion (meibum)
after digital pressure application on the lids.13–15
Table 1 Baseline data
Patient 1 Patient 2 Patient 3 Patient 4
Sex Female Female Female Male
Age (years) 56 64 25 41
Ocular anamnesis DED, PEDs
and RCEs
DED, PEDs
and RCEs
DED, PEDs and RCEs DED, PEDs and RCEs after
herpes simplex keratitis in L.E.
General anamnesis Unremarkable Unremarkable T1DM, anemia, food allergies and autoan-
tibodies positivity.
Unremarkable
Affected eye (PEDs/RCEs) Right Left Right Left
BCVA R.E- L.E (logMAR) 0.00–0.00 0.10–0.10 0.00–0.00 0.00–0.00
IOP R.E.- L.E.(mmHg) 14–15 18–20 17–16 19–18
McM (score) 15 17 29 16
OSDI (score) 30.5 33.3 70.8 30.2
FBUT R.E. (s) 4 3 3 4
FBUT L.E. (s) 3 2 3 5
Oxford R.E (grade) 0 1 0 0
Oxford L.E. (grade) 0 2 0 0
Schir. R.E. (mm) 2 1 4 7
Schir. L.E. (mm) 1 0 6 7
Meib. R.E. (grade) Normal Normal Poor Normal
Meib. L.E. (grade) Normal Normal Poor Normal
RCEs episodes (rate) 1 per month 1 per month >3 per month 1 per month
Abbreviations: PEDs, persistent epithelial defects; DED, dry eye disease; RCEs, recurrent corneal erosions; HSV, herpes simplex virus; T1DM, type 1 diabetes mellitus;
BCVA, best corrected visual acuity; McM, McMonnies Dry Eye Questionnaire (score); OSDI, Ocular Surface Disease Index (score); FBUT R.E/L.E., ﬂuorescein break-up time
in right eye/left eye expressed in seconds; Oxford R.E/L.E., ﬂuorescein staining of the cornea and conjunctiva (according to the Oxford grading system) in right eye/left eye;
Schir. R.E/L.E, Schirmer I test in the right/left eye (expressed in mm); Meib. R.E/L.E., meibomian secretion (meibum) after digital pressure application on the upper lid tarsus;
RCEs episodes, presence of episodic RCEs symptoms (acute pain and photophobia).
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This set of exams was repeated in each visit during the
follow-up period of 12 months (Table 2). Each examina-
tion was completed within 25–30 mins and in the
same day time (from 3 pm to 5 pm).
Results
Overall, the mean patient age at the ﬁrst evaluation was
46.5 years (range 25 to 64).
Baseline
All patients presented to our attention were complaining
DED symptoms (ie, dryness, soreness, scratchiness, burning,
and grittiness) in both eyes for at least two years. Beyond the
DED symptoms, our patients claimed recurrent episodes of
pain, redness, and photophobia (RCEs) in the eye affected by
PEDs. These painful episodes usually started in the morning,
on the ﬁrst awakening, and lasted about two or three days.
Figure 1 Ocular surface with epithelial abnormalities. After the instillation of ﬂuorescein dye in the tear ﬁlm (blue cobalt light with yellow ﬁlter written n.12), the ocular
surface revealed multiple patterns of epithelial abnormalities, which are seen as non-colored areas of the tear ﬁlm (located at the same site during the various blinking).
Clearly, the latter represent irregularities of the epithelial–basal membrane complex. When recurrent erosions occur, the site of epithelial defects corresponds to those of
the epithelial blisters. If an epithelial defect lasts more than two weeks, it can be considered as “persistent” (or PED).
Figure 2 Ocular surface with a persistent epithelial defect (PED). Epithelial defects are considered as “persistent” when they last at least 2 weeks without regression. In this
image, after the instillation of ﬂuorescein dye in the tear ﬁlm (blue cobalt light with yellow ﬁlter Written n.12), this patient clearly showed a paracentral area of epithelial loss,
which was refractory to the ﬁrst-line treatment.
Napoli et al Dovepress
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At the ﬁrst evaluation, all patients revealed a variable
degree of DED. Among them, three patients had a mild
DED (McMonnies score between 10 and 20, and OSDI
score between 23 and 32) and one patient had a severe
DED (McMonnies score was more than 20 and OSDI
more than 33). Each patient showed a low value of
FBUT in both eyes (lower than 10 s) ranged from 2 to 4 s.
The quantitative evaluation of tear production was
revealed with the Schirmer I Test, which was markedly
reduced in the two older patients (from 0 to 2 mm in both
eyes), and slightly reduced in the other two patients (from 4
to7 mm in both eyes).
The ﬂuorescein staining of the cornea and conjunctiva,
based on the Oxford Grading System, revealed no punctate
staining in three patients and moderate staining in both
eyes of the older patient.
Moreover, the meibomian secretion and the BCVAwere
reduced in the older patient. BVCA was 0.00 LogMAR in
both eyes of three patients, and 0.10 in both eyes of the
older patient.
Intraocular pressure (IOP) measured at the ﬁrst check was
in the range of normality (from 14 to 20 mmHg) (Table 1).
On the 15th day after therapy
Two weeks after the beginning of cyclosporine eye drops
therapy, the clinical status of the patient tended to ame-
liorate in signs without subjective improvement, as fol-
lows: McMonnies Dry Eye Questionnaire score was
slightly reduced in all patients, but their grade of DED
gravity showed no changes (3 moderate and 1 severe).
OSDI score improved in all patients. One of these was
ameliorated from moderate (30.2) to normal score (11.3),
and the other one was ameliorated from severe (33.3) to
moderate score (30.5)
The other parameters examined (FBUT, Oxford score,
Schirmer I test and meibomian secretion) showed no
Table 2 Results during therapy
Time after cyclospor-
ine A 0.05% eye drops
onset
Eye with PEDs FBUT (s) Oxford Schir.
(mm)
Meibum RCEs
ep.
McM OSDI R.E. L.E. R.E L.E. R.E. L.E. R.E. L.E.
Patient 1 Baseline Right 15 30.5 4 3 0 0 2 1 N. N. Yes
15 days 13 25 3 3 0 0 5 10 N. N. Yes
2 months 8 0 6 6 0 0 9 5 N. N. No
6 months 10 0 7 8 0 0 10 12 N. N. No
12 months 8 0 8 10 0 0 10 10 N. N. No
Patient 2 Baseline Left 17 33.3 3 2 1 2 1 0 N. N. Yes
15 days 16 30.5 4 3 1 1 3 2 N. N. Yes
2 months 12 11.3 4 4 0 0 5 6 N. N. No
6 months 10 6,3 8 9 0 0 7 5 N. N. No
12 months 9 4.5 12 11 0 0 7 6 N. N. No
Patient 3 Baseline Right 29 70.8 3 3 0 0 4 6 P. P. Yes
15 days 27 68.2 4 2 0 0 5 6 P. P. Yes
2 month 19 34 6 5 0 0 12 11 P. P. No
6 months 15 22.7 6 7 0 0 12 12 P. P. No
12 months 13 18.1 7 7 0 0 10 11 P. P. No
Patient 4 Baseline Left 16 30.2 3 2 0 0 7 7 N. N. Yes
15 days 14 11.3 3 4 0 0 6 5 N. N. Yes
2 months 6 0 9 11 0 0 10 12 N. N. No
6 months 5 0 12 11 0 0 12 11 N. N. No
12 months 6 4 13 12 0 0 10 12 N. N. No
Abbreviations: PEDs, persistent epithelial defects; McM, McMonnies Dry Eye Questionnaire (score); OSDI, Ocular Surface Disease Index (score); FBUT R.E/L.E.,
ﬂuorescein break-up time in right eye/left eye expressed in seconds; Oxford R.E/L.E., ﬂuorescein staining of the cornea and conjunctiva (according to the Oxford grading
system) in right eye/left eye; Schir. R.E/L.E, Schirmer I test in the right/left eye (expressed in mm); Meibum R.E/L.E., meibomian secretion (meibum) after digital pressure
application on the upper lid tarsus (N=Normal; P=Pathologic); RCEs ep., presence of episodic RCEs symptoms (acute pain and photophobia).
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changes from the ﬁrst evaluation. At this time, RCEs
continued to persist in all patients (Table 2).
On the 2nd month after therapy
At the following examination, two months after the onset
of cyclosporine therapy, all patient referred to feel their
eyes more wet than in the past and to have a signiﬁcant
increase in eye comfort sensation.
We observed an important improvement of the clinical
status compared to baseline. Indeed, McMonnies Dry Eye
Questionnaire score was substantially improved in all
patients. Two patients, compared to baseline, switched
from mild to normal grade (the score changed from 15 to
8 and from 16 to 6). One patient ameliorated from severe to
mild grade (from 29 to 19) and in one patient the
McMonnies evaluation remained mild (with a score reduc-
tion from 17 to 12). Similarly to McMonnies, OSDI ques-
tionnaire revealed an improvement of the ocular discomfort
in all participants. All subjects disclosed an important score
reduction in OSDI value as follows: two mild patients and
one severe patient raised to a normal status (from 30.5,
33.3, and 30.5 to 0, 11.3, and 11.3, respectively). Only
one patient remained at the same severe status, although
she showed a considerable reduction of her score, from 70.8
(at baseline) to 34 (subsequently).
The FBUTwas increased, in relation to the baseline value,
in all eyes from 1 to 9 s (average value was 3.5 s). In addition,
the Schirmer I Test showed an ameliorated outcome. All eyes
revealed an increased production of tears from 3 to 7 mm
(average value was 5 mm). Fluorescein staining score was
zero in all eyes (at baseline, one eye revealed a score of 1, and
another eye disclosed a score of 2). Meibomian secretion was
unchanged. The episodes of RCEs were for the ﬁrst time
reduced in all patients.
Overall, two patients had no recurrences of ocular pain,
redness, and photophobia, and two patients showed
a reduction in frequency of RCEs symptoms (Table 2).
On the 6th month after therapy
On the 6th month, all patients disclosed a stabilization of
clinical pictures.
McMonnies evaluation had no signiﬁcant changes,
but one patient improved from a mild (12) to a normal
grade (10). One patient remained in a mild grade and two
participants remained in a normal score. OSDI question-
naire showed only one ameliorated patient (from mild to
slight score). Other subjects showed no changes in the
grading score.
FBUT, Schirmer I Test, ﬂuorescein staining score, and
meibomian secretion were analog to the previous visit.
At this examination, for the ﬁrst time, all the subjects
revealed a clinical improvement of DED signs and symp-
toms, related to the absence of new RCE episodes
(Table 2).
On the 12th month after therapy
On the 12th month, no substantial differences in symptoms
and signs were observed. Clinical pictures were similar to
previous visit. All subjects revealed, as reported in the 6th
month, the absence of RCEs symptoms (Table 2).
Discussion
The results of our case series demonstrated that the treat-
ment with cyclosporine eye drops was useful in reducing
the RCEs and the concomitant tear ﬁlm dysfunctions in
patients with refractory PEDs. In addition, the latter also
beneﬁted from the topical immunomodulatory therapy,
with the complete healing of areas of epithelial loss.
Therefore, topical cyclosporine proved here to be useful
to manage complex and recalcitrant cases of ocular surface
damage with associated comorbidities.
As previously reported, patients with chronic DED, if
untreated, may develop ocular surface damage over time.9
Consequently, the mechanical stress due to the reduced
lubriﬁcation may lead to continuous erosion and abnormal
scarring in corneal and conjunctival tissue.
On the other hand, RCEs (and related PEDs) are painful
conditions due to episodes of breakdown of corneal epithe-
lium, which are characterized by a defect adhesion of
epithelium to the basal membrane (E-BM). In these parti-
cular situations, the mechanical and physiological stress due
to the lid movements (during blinking) may be increased by
dry eye status (eg, DED) and may predispose to episodic
tear or pop of epithelial blisters (Figures 1 and 2).
As is known, the treatment of PEDs is based on different
therapeutic strategies, which generally lead to a variety of
poorly predictable outcomes. Lubrication is usually the ﬁrst
step. Punctal plugs are useful to increase the retention of
natural tears, which facilitates the wound healing process.
However, if used in severe inﬂammatory disorders, they can
exacerbate both the epithelial defect and DED. Soft thera-
peutic contact lenses are used to protect the corneal surface
from mechanical trauma from the eyelids. Tarsorrhaphy is
used to allow the ocular surface to heal itself. However, it is
clearly reserved for noncompliant or debilitated patients, as
well as for patients with lagophthalmos or exposure
Napoli et al Dovepress
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keratopathy. Oral tetracycline (250 mg four times daily) and
doxycycline (20–100 mg twice daily), which have anti-
collagenolytic properties, may aid in corneal wound healing
and prevent stromal lysis. Prophylactic topical antibiotics
are used to prevent the risk of infection. Again, the use of
topical steroids such as loteprednol or prednisolone twice
daily tends to be very helpful. In the most serious and
refractory cases, the following measures are taken: human
amniotic grafting, autologous serum eye drops, and scleral
contact lenses.1
However, in some cases, PEDs may be non-responsive to
various therapeutic strategies, and the patient may be reluc-
tant or unable to undergo invasive or complex treatments.
Topical cyclosporine is an immunomodulatory drug with
anti-inﬂammatory effects, which is able to inhibit IL-2 acti-
vation of lymphocytes. Accordingly, immunomodulation
aims to attenuate the immune response to an adaptive rather
than maladaptive level, thus promoting healing of the tissue
damages. For instance, a regulatory adjustment of the
immune system with cyclosporine A 1% eye drops was
demonstrated to be an effective approach in the clinical
picture of the ocular graft-versus-host-disease.16 In the latter
context, white blood cells (T cells) of the donor’s immune
system which remain within the donated tissue (the graft)
recognize and attack the recipient (the host) as foreign (non-
self), thus determining a speciﬁc medical complication of
allotransplant (in the absence of RCEs or defects of adhesion
between epithelium and basal membrane).
The novelty of the present study is that topical therapy
with cyclosporine A 0.05%, in PED patients with DED
and RCEs, has proved to be useful in improving the tear
ﬁlm stability and in reducing the relapse of epithelial
ruptures. Again, our results showed that the recurrence
rate of corneal erosions improved in parallel with the
improvement of DED signs and symptoms. Therefore,
the data of this work suggest that the reduction of ocular
surface inﬂammation and the improvement of lubrication
may reduce the mechanical stress that leads to a potential
tear or pop of epithelial blisters. In fact, a clinically sig-
niﬁcant amelioration was disclosed in tear production,
ocular surface integrity, BUT and ocular symptoms, thus
indicating a potentially central role of the immunomodu-
latory therapy on regulation of the homeostasis of the
ocular surface in these particular cases.
Speciﬁcally, ocular surface inﬂammation may lead
T lymphocytes to the release of inﬂammatory mediators
that damage the surface epithelium.17 This, in turn, results
in a reduction of mucin production and in further loss of
homeostasis. Conversely, less inﬂammation implies an
improvement in the quality of the epithelium, which leads
to an increased reﬂex tearing with a greater supply of nutri-
ents, growth factors and protective substances for the ocular
surface epithelia (eg, secretory IgA, lysozyme, lactoferrin, or
hepatocyte growth factor and epidermal growth factor that
are essentials for the maintenance of the epithelium). In our
analysis, this was reﬂected in the better Schirmer test and
ﬂuorescein staining scores. Similarly, an improvement in the
interface between the aqueous tear layer and the hydrophobic
epithelium due to a better mucin production would explain
the increase in BUT results.18
Thus, we believe that cyclosporine eye drop is
a promising therapeutic strategy, mainly because it was
very effective in stabilizing the health status of the ocular
surface in absence of any systemic or local side effect.
Clearly, this aspect was very important for our patients,
since PEDs and associated comorbidities may be difﬁcult to
treat and can require long-term therapy. Interestingly, some
clinical trials demonstrated that topical cyclosporine therapy
can be well tolerated for up to 3 years without major adverse
effects.19,20 In this sense, it should be further taken into
consideration and studied as primary therapy, or in addition
to initial therapy to maximize its effectiveness, and in
patients with elevated risk of relapse of epithelial ruptures.
In conclusion, despite the low sample size due to the
narrow inclusion criteria for this study, topical cyclospor-
ine medication can be considered an interesting, safe and
effective treatment option in the management of refractory
PEDs with associated ocular comorbidities.
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